BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for ...

TOKYO and BOSTON, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Jnana Therapeutics Inc. (Jnana) today announced that they have entered into a definitive merger ...

Japan's Otsuka Pharma has agreed to take control of US biotech Jnana Therapeutics in a deal that will give it rights to a clinical-stage candidate for the rare metabolic disorder phenylketonuria (PKU) ...

Otsuka Pharmaceutical has picked up Boston-based Jnana Therapeutics for $800 million so the Japanese biotech can get its hands on a clinical-stage oral phenylketonuria (PKU) drug. Under the terms of ...

BOSTON--(BUSINESS WIRE)--Jnana Therapeutics, a biotechnology company targeting the solute carrier (SLC) family of metabolite transporters to treat underserved diseases, today announced that it has ...

Every Monday night—travel schedules permitting—Stuart Schreiber and Ramnik Xavier meet with a small team of researchers at Jnana Therapeutics, a company they cofounded, to discuss the start-up’s ...

BOSTON--(BUSINESS WIRE)--Jnana Therapeutics today announced a strategic, multi-target collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery of small molecule ...

Roche has another drug discovery deal on the books. This time, it’s with Jnana Therapeutics, the biotech targeting a family of more than 400 metabolite transporters with small molecules. The Big ...

TOKYO, Aug 1 (Reuters) - Japan's Otsuka Pharmaceutical (4578.T), opens new tab said on Thursday it agreed to pay more than $1 billion to acquire Jnana Therapeutics as it looks to expand its drug ...

A Boston biotech founded by researchers at the Broad Institute of MIT and Harvard has landed $157 million for its big plans to develop pills for cancer, immune conditions, neurological diseases, and a ...